RareCyte now offers a liquid biopsy blood test for programmed death-ligand 1 (PD-L1) that evaluates PD-L1 expression on circulating tumor cells (CTCs). The PD-L1 assay and the AccuCyte-CyteFinder system processes a single tube of blood to cells for CTC enumeration and PD-L1 biomarker expression analysis, and to plasma for optional cfDNA analysis. Single CTCs can also be retrieved using the CytePicker Module for sequencing analysis. Results from the test can help direct checkpoint inhibitor immunotherapy treatment and liquid biopsy offer a noninvasive method to evaluate biomarker expression for treatment selection and patient monitoring in clinical research.
RareCyte
